EE03605B1 - Protsess amorfse [R-(R*,R*)]-2-(4-fluorofenüül)-ß,š-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino) -karbonüül]-1H-pürrool-1-heptaanhappe kaltsiumsoola (2:1) tootmiseks - Google Patents

Protsess amorfse [R-(R*,R*)]-2-(4-fluorofenüül)-ß,š-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino) -karbonüül]-1H-pürrool-1-heptaanhappe kaltsiumsoola (2:1) tootmiseks

Info

Publication number
EE03605B1
EE03605B1 EE9700369A EE9700369A EE03605B1 EE 03605 B1 EE03605 B1 EE 03605B1 EE 9700369 A EE9700369 A EE 9700369A EE 9700369 A EE9700369 A EE 9700369A EE 03605 B1 EE03605 B1 EE 03605B1
Authority
EE
Estonia
Prior art keywords
phenylamino
methylethyl
fluorophenyl
pyrrole
dihydroxy
Prior art date
Application number
EE9700369A
Other languages
English (en)
Estonian (et)
Other versions
EE9700369A (et
Inventor
Lin Min
Schweiss Dieter
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21696097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03605(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of EE9700369A publication Critical patent/EE9700369A/xx
Publication of EE03605B1 publication Critical patent/EE03605B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
EE9700369A 1995-07-17 1996-07-16 Protsess amorfse [R-(R*,R*)]-2-(4-fluorofenüül)-ß,š-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino) -karbonüül]-1H-pürrool-1-heptaanhappe kaltsiumsoola (2:1) tootmiseks EE03605B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US145395P 1995-07-17 1995-07-17
PCT/US1996/011807 WO1997003960A1 (fr) 1995-07-17 1996-07-16 NOUVEAU PROCEDE POUR LA PRODUCTION DE SEL DE CALCIUM D'ACIDE AMORPHE [R-(R*,R*))-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-(PHENYLAMINO)CARBONYLE]-1H-PYRROL-1-HEPTANOIQUE (2:1)

Publications (2)

Publication Number Publication Date
EE9700369A EE9700369A (et) 1998-06-15
EE03605B1 true EE03605B1 (et) 2002-02-15

Family

ID=21696097

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700369A EE03605B1 (et) 1995-07-17 1996-07-16 Protsess amorfse [R-(R*,R*)]-2-(4-fluorofenüül)-ß,š-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino) -karbonüül]-1H-pürrool-1-heptaanhappe kaltsiumsoola (2:1) tootmiseks

Country Status (37)

Country Link
US (1) US6274740B1 (fr)
EP (1) EP0839132B1 (fr)
JP (1) JP4064459B2 (fr)
KR (1) KR100400805B1 (fr)
CN (1) CN1087289C (fr)
AR (1) AR002849A1 (fr)
AT (1) ATE199542T1 (fr)
AU (1) AU700794B2 (fr)
BG (1) BG63631B1 (fr)
BR (1) BR9609714A (fr)
CA (1) CA2220455C (fr)
CO (1) CO4700441A1 (fr)
CZ (1) CZ289421B6 (fr)
DE (1) DE69611999T2 (fr)
DK (1) DK0839132T5 (fr)
EA (1) EA000625B1 (fr)
EE (1) EE03605B1 (fr)
ES (1) ES2156997T3 (fr)
GE (1) GEP20002027B (fr)
GR (1) GR3035859T3 (fr)
HR (1) HRP960312B1 (fr)
HU (1) HU220343B (fr)
IL (1) IL122161A (fr)
IN (1) IN185276B (fr)
MX (1) MX9708959A (fr)
NO (1) NO309322B1 (fr)
NZ (1) NZ313008A (fr)
PE (1) PE1698A1 (fr)
PL (1) PL191017B1 (fr)
PT (1) PT839132E (fr)
RO (1) RO120069B1 (fr)
SI (1) SI0839132T1 (fr)
SK (1) SK283204B6 (fr)
UA (1) UA50743C2 (fr)
UY (1) UY24286A1 (fr)
WO (1) WO1997003960A1 (fr)
ZA (1) ZA966043B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
IN191236B (fr) 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US6646133B1 (en) 2000-10-17 2003-11-11 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
PL362981A1 (en) 2000-11-16 2004-11-02 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (fr) 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Formes cristallines d'atorvastatine
WO2002057228A1 (fr) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatine calcique
WO2002057229A1 (fr) 2001-01-19 2002-07-25 Biocon India Limited FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (fr) * 2001-04-11 2003-08-09 Cadila Heathcare Ltd
BR0210666A (pt) * 2001-06-29 2004-10-05 Warner Lambert Co Formas cristalinas do sal de cálcio do ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-dihidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)c arbonil]-1h-pirrol-1-heptanóico (2:1) (atorvastatina)
US7361772B2 (en) 2001-08-16 2008-04-22 Biocon Limited Process for the production of atorvastatin calcium
US7563911B2 (en) 2001-08-31 2009-07-21 Morepen Laboratories Ltd. Process for the preparation of amorphous atorvastin calcium salt (2:1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
HUP0500074A3 (en) 2002-03-18 2005-07-28 Biocon Ltd Bangalore Amorphous hmg-coa reductase inhibitors of desired particle size and process for producing them
RU2309141C2 (ru) * 2002-03-18 2007-10-27 Байокон Лимитид АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
WO2003099785A1 (fr) * 2002-05-28 2003-12-04 Cadila Healthcare Limited Procede de preparation de calcium atorvastatine amorphe
US7179942B2 (en) 2002-07-05 2007-02-20 Bicon Limited Halo-substituted active methylene compounds
WO2004022053A1 (fr) * 2002-09-03 2004-03-18 Morepen Laboratories Limited Forme vi de calcium d'atorvastatine ou hydrates de cette derniere
AU2004228607B2 (en) * 2003-04-11 2011-01-27 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
ES2323366T3 (es) 2003-04-22 2009-07-14 Biocon Limited Procedimiento novedoso para la reduccion estereoselectiva de beta-cetoesteres.
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
AU2003272080A1 (en) 2003-09-18 2005-04-06 Biocon Limited Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
CA2456430A1 (fr) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Procede ameliore pour la preparation d'atorvastatine calcique amorphe
CZ298382B6 (cs) * 2004-03-10 2007-09-12 Zentiva, A. S. Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace
WO2005092852A1 (fr) 2004-03-17 2005-10-06 Ranbaxy Laboratories Limited Procede de production d'atorvastatine calcique sous forme amorphe
CA2649054A1 (fr) 2004-05-05 2005-11-10 Pfizer Products Inc. Formes salines d'acide [r-(r*, r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique
CA2573969C (fr) * 2004-07-16 2014-02-04 Lek Pharmaceuticals D.D. Produits de degradation oxydante du calcium d'atorvastatine
US7645888B2 (en) 2004-08-27 2010-01-12 Biocon Limited Process for the production of amorphous atorvastatin calcium
EP1793815A4 (fr) * 2004-09-30 2010-12-29 Reddys Lab Ltd Dr Atorvastatine calcique amorphe
CN101039906A (zh) * 2004-10-18 2007-09-19 特瓦制药工业有限公司 通过将盐溶解于有机溶剂并除去该溶剂来制备无定形阿托伐他汀半钙的方法，所述有机溶剂为醇和酮和 /或酯的混合物
WO2006046109A1 (fr) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Procede de formation d'atorvastatine amorphe
WO2006054308A2 (fr) 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Formulations d'atorvastatine stables
JP2008521878A (ja) * 2004-12-02 2008-06-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 非晶質アトルバスタチンの医薬組成物及びその製造のための方法
US20080108664A1 (en) 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
EP1810667A1 (fr) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Composition pharmaceutique contenant de l'atorvastatin amorphé
EP1877375A1 (fr) * 2006-03-01 2008-01-16 Teva Pharmaceutical Industries Ltd Procede de preparation d'une forme cristalline d'hemi-calcium d'atorvastatine
WO2008053312A2 (fr) * 2006-11-02 2008-05-08 Cadila Pharmaceuticals Limited Procédé de préparation d'un sel d'hémicalcium d'atorvastatine amorphe et intermédiaire de ce dernier
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
WO2009007856A2 (fr) * 2007-07-11 2009-01-15 Actavis Group Ptc Ehf Nouveau polymorphe d'atorvastatine calcium et son utilisation pour la préparation d'atorvastatine calcium amorphe
US20090124817A1 (en) * 2007-11-09 2009-05-14 The Industry & Academic Cooperation In Chungnam National University Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles
EP2075246A1 (fr) 2007-12-27 2009-07-01 M. J. Institute of Research Procédé de préparation de forme amorphe de sel hémicalcium atorvastanine
WO2010066846A2 (fr) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Procédé pour isoler de l'atorvastatine
EP2373609B1 (fr) 2008-12-19 2013-10-16 KRKA, D.D., Novo Mesto Utilisation de composés amphiphiles pour la cristallisation régulée de statines et d'intermédiaires de statines
EP2327682A1 (fr) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Utilisation de composés amphiphiles pour la crystallisation controlée de statines et d'intermediaires de statines.
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
GEP20002029B (en) 1995-07-17 2000-04-10 Warner Lambert Company Us (54) Crystalline [R-(R*,R*,]–2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methyl-Ethyl)-3-Phenyl–4-{Phenylamino) Carbonyl} - 1H - Pyrrole - 1 - Heptanoic Acid Hemi Calcium Salt (Atorvastatin)

Also Published As

Publication number Publication date
IN185276B (fr) 2000-12-16
PL191017B1 (pl) 2006-03-31
BG102188A (en) 1998-08-31
NO309322B1 (no) 2001-01-15
SK283204B6 (sk) 2003-03-04
CA2220455C (fr) 2002-09-24
EA199800128A1 (ru) 1998-08-27
ATE199542T1 (de) 2001-03-15
EP0839132A1 (fr) 1998-05-06
EE9700369A (et) 1998-06-15
HRP960312B1 (en) 2001-10-31
IL122161A (en) 1999-07-14
HUP9903017A3 (en) 2001-01-29
SI0839132T1 (fr) 2001-06-30
DE69611999D1 (de) 2001-04-12
KR100400805B1 (ko) 2003-12-24
KR19990029045A (ko) 1999-04-15
UY24286A1 (es) 1997-01-17
UA50743C2 (uk) 2002-11-15
IL122161A0 (en) 1998-04-05
ES2156997T3 (es) 2001-08-01
ZA966043B (en) 1997-02-03
PT839132E (pt) 2001-06-29
PE1698A1 (es) 1998-02-19
CN1190956A (zh) 1998-08-19
SK5898A3 (en) 1998-08-05
HK1018054A1 (en) 1999-12-10
CN1087289C (zh) 2002-07-10
RO120069B1 (ro) 2005-08-30
JPH11510486A (ja) 1999-09-14
GR3035859T3 (en) 2001-08-31
MX9708959A (es) 1998-03-31
HU220343B (hu) 2001-12-28
EP0839132B1 (fr) 2001-03-07
CA2220455A1 (fr) 1997-02-06
WO1997003960A1 (fr) 1997-02-06
NO980209L (no) 1998-01-16
GEP20002027B (en) 2000-04-10
BR9609714A (pt) 1999-02-23
BG63631B1 (bg) 2002-07-31
US6274740B1 (en) 2001-08-14
EA000625B1 (ru) 1999-12-29
DK0839132T3 (da) 2001-04-09
NZ313008A (en) 2000-01-28
CZ12298A3 (cs) 1998-12-16
AU6497896A (en) 1997-02-18
AR002849A1 (es) 1998-04-29
NO980209D0 (no) 1998-01-16
JP4064459B2 (ja) 2008-03-19
DE69611999T2 (de) 2001-07-26
AU700794B2 (en) 1999-01-14
PL324463A1 (en) 1998-05-25
DK0839132T5 (da) 2006-03-20
CO4700441A1 (es) 1998-12-29
HRP960312A2 (en) 1998-02-28
CZ289421B6 (cs) 2002-01-16

Similar Documents

Publication Publication Date Title
EE03605B1 (et) Protsess amorfse [R-(R*,R*)]-2-(4-fluorofenüül)-ß,š-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino) -karbonüül]-1H-pürrool-1-heptaanhappe kaltsiumsoola (2:1) tootmiseks
ZA966044B (en) Crystalline [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1).
TWI319396B (en) Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
DK1061073T3 (da) [R-(R*,R*)]-2-(4-Fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)-carbonyl]-1H-pyrrol-1-heptansyre, lactonformen og salte deraf
NO975499D0 (no) Form III krystallinsk (R-(R*,R*)-2(4-fluorfenyl)-<beta>-<delta>-dihydroksy-(1-metyl-etyl)-3-fenyl-4-(fenylamino)karbonyl)-1H-pyrrol-1-heptansyre-hemi-kalsiumsalt
DE69616358D1 (de) Kristalline form iii des hemi calcium salzes von [r-(r*,r*)]-2-(4-fluorphenyl)-beta-delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure (atorvastatin)
NZ507836A (en) Crystalline [r*(r* ,r*)]-2-(4-flurophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
HK1056556A (en) HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-β, δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE
ZA200303974B (en) Hydrolysis of [R(R*,R*)]-2-(4-Fluorophenyl)-b,D-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic acid esters with calcium hydroxide.
AU2001234058A1 (en) Form v crystalline (r-(r*,r*))-2-(4-fluorophenyl)-ss,$g(d)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1- heptanoic acid hemi calcium salt. (atorvastatin)

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name